Safety and Efficacy of Radiotherapy Combined with Immunotherapy for Advanced Malignant Tumors.

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

August 1, 2025

Primary Completion Date

July 31, 2026

Study Completion Date

December 31, 2026

Conditions
Advanced Solid Tumor
Interventions
COMBINATION_PRODUCT

Radiotherapy combined with immunotherapy

(1) SBRT 8Gy×3f, (2) LDRT 2Gy ×3f, PD-1/L1 inhibitor, periodically, until the disease progresses or intolerable toxic side effects, (4) GM-CSF, 200ug/QD, subcutaneous injection, the first course of treatment for 7 days.

Trial Locations (1)

100853

RECRUITING

China-Japan Friendship Hospital, Beijing

All Listed Sponsors
lead

China-Japan Friendship Hospital

OTHER

NCT06173219 - Safety and Efficacy of Radiotherapy Combined with Immunotherapy for Advanced Malignant Tumors. | Biotech Hunter | Biotech Hunter